Medical-Grade Manuka Honey and Manuka Honey Extract Inhibit Mast Cell Degranulation through inhibition of MRGPRX2 expression: Potential Intravesical Agent for the Management of Interstitial Cystitis/Bladder Pain Syndrome?

The study focuses on neurogenic inflammation in interstitial cystitis/bladder pain syndrome (IC/BPS), where substance P triggers mast cell degranulation via MRGPRX2 receptors, releasing pro-inflammatory mediators. Medihoney, a medical-grade manuka honey, was shown to suppress this pathway in vitro, implying it could be administered intravesically to reduce chronic bladder inflammation. The authors propose that targeting MRGPRX2 with manuka honey may offer a novel, non-antibiotic approach to managing IC/BPS. Further validation in animal models and clinical trials is needed to confirm efficacy and safety.